Developer docs
API playgroundTry for free, no card

Search company profiles

Clearmind Biomedical

Full company profile

uuid0006la7

Namestring
Clearmind Biomedical
Legal namestring
ClearMind Biomedical Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

ClearMind Biomedical Inc. is a privately held medical device company founded in 2014 with backing from Y Combinator and origins in the Stanford-Taiwan Biomedical Fellowship Program. The company develops and commercializes minimally invasive neurosurgical endoscopy systems for the treatment of intracerebral hemorrhage (ICH), the deadliest form of stroke with reported death rates of 36-60%. Its core technology is a 6.5mm access channel micro-invasive platform that consolidates visualization, illumination, irrigation, suction, coagulation, and powered debridement into single-use neuroendoscope handpieces controlled via reusable high-definition touchscreen monitors.

The product portfolio centers on two generations of the platform. The Axonpen System, FDA 510(k) cleared in the US in 2020 and in Taiwan in 2021, is the first generation multifunctional neuroendoscope with a bendable tip. The Neuroblade System, FDA 510(k) cleared in August 2024, is the second-generation all-in-one device combining bipolar coagulation, morcellator debridement, lens cleaning, suction, and irrigation and is composed of the disposable Neuroblade endoscope, the reusable 15-inch Neuropad touchscreen monitor, and the disposable Clearpath transparent access sheath that integrates with optical and electromagnetic surgical navigation systems. The company has filed 21 patents supporting the Neuroblade platform.

ClearMind operates from dual headquarters in San Jose, California (US) and New Taipei City, Taiwan, employing 11-50 staff across both locations. Its revenue model is enterprise medical device sales of hardware plus disposables, distributed via direct hospital sales targeting neurosurgery departments, with named clinical reference sites at Mt. Sinai Hospital in New York (first US Neuroblade surgery, Dr. Christopher Kellner) and Chang Gang Memorial Hospital in Taiwan (FIM clinical trial site). The company has completed seed, Series A (2017), and Series B (2022, including Darwin Venture Management) funding rounds, leadership comprises CEO Carrey Yang, CTO/CFO Paul Chan, VP & GM Americas J. Dustin Duckett, and BD Manager Penny Huang, and the company pursues a stated objective of enabling a single surgeon to complete ICH procedures in one hour at regional hospitals.

Short descriptiontext

ClearMind Biomedical is a privately held medical device company that develops minimally invasive neurosurgical endoscopy systems for treating intracerebral hemorrhage (hemorrhagic stroke), combining visualization, suction, irrigation, coagulation, and debridement into single-use devices sold to hospital neurosurgery departments in the US and Taiwan.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTaipei, Taiwan
HQ citystring
Taipei
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurosurgical endoscopy systems, minimally invasive neurosurgery, intracerebral hemorrhage treatment, neuroendoscopic medical devices, hemorrhagic stroke devices
Industry3 codes
PRIMARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHAEAL
Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neurosurgical Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Neuroblade System Sales
TypeHardware Sales
Description

Sale of the Neuroblade System comprising disposable components (Neuroblade endoscope, Clearpath sheath) and reusable hardware (Neuropad monitor). Medical device capital and consumables model.

clearmindbiomedicalgroup.com
2Axonpen System Sales
TypeHardware Sales
Description

Sale of Axonpen System including disposable endoscope components and reusable monitor (Axon Monitor).

clearmindbiomedicalgroup.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Axonpen System
Description

Multifunctional neuroendoscope for ICH treatment with disposable endoscope, coagulation system integration, debrider, suction/irrigation, and bendable tip. Features high definition visualization with Axon Monitor.

clearmindbiomedicalgroup.com
+2 more records
Core offering1 text field

Clearmind Biomedical manufactures and sells micro-invasive neurosurgical endoscopy systems used by neurosurgeons in hospitals to treat intracerebral hemorrhage (ICH) and brain hemorrhage. The product portfolio centers on two FDA 510(k)-cleared platforms - the Axonpen System (multifunctional neuroendoscope with bendable tip and 6.5mm access) and the Neuroblade System (an all-in-one disposable neuroendoscope integrating visualization, illumination, irrigation, suction, coagulation, and powered debridement, used with a reusable touchscreen monitor and disposable access sheath). Devices are sold to hospital neurosurgery departments via direct sales and procurement.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 5% mortality rate (vs 35-50% traditional)
+4 more records
Product overview1 text field

Clearmind Biomedical is a medical device company offering a portfolio of minimally invasive neurosurgical systems for the treatment of intracerebral hemorrhage (ICH) and brain hemorrhage. The portfolio consists of two primary product platforms — the Axonpen System and the Neuroblade System — both designed around the company's proprietary micro-invasive technology to enable least-invasive brain surgery. The Axonpen System is a multifunctional endoscope combining visualization, suction, irrigation, and a bendable tip with its companion Axon Monitor, suited for ICH and subdural hematoma procedures. The Neuroblade System is a newer-generation all-in-one platform comprising three components: the Neuroblade single-use neuroendoscope (with integrated coagulation, debridement, suction, and irrigation), the Neuropad reusable touchscreen tablet interface, and the Clearpath disposable transparent access sheath (which also integrates with optical and EM surgical navigation systems). Both platforms target the same clinical indication — ICH evacuation — with a stated objective of enabling a single surgeon to complete procedures in one hour at regional hospitals.

Product and service2 records
1Axonpen System
CategoryNeurosurgical Endoscopy Systems
Description

A multifunctional neurosurgical endoscope system for the treatment of intracerebral hemorrhage (ICH) and subdural hematomas, combining tissue visualization, suction, irrigation, and a bendable tip into a single minimally invasive operating platform. Requires only a 6.5mm skull channel for brain access, integrates with coagulation systems and homeostasis applicators, and includes the Axon Monitor for high-definition visualization and intraoperative screenshot capture. Targeted at neurosurgery departments in hospitals.

2Neuroblade System
CategoryNeurosurgical Endoscopy Systems
Description

An all-in-one, single-use multifunctional neuroendoscopic system for minimally invasive ICH surgery, integrating bipolar coagulation, morcellator debrider, lens cleaning technology, suction, and irrigation into a single handpiece. The platform comprises three components: Neuroblade (disposable endoscope), Neuropad (reusable 15-inch high-definition touchscreen monitor), and Clearpath (disposable transparent access sheath). FDA 510(k) cleared in 2024 for use by neurosurgeons in hospitals.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFoundationalTypeStrategic or Co-development Partner
Description

ClearMind founders were members of the Stanford-Taiwan Biomedical Fellowship Program, which inspired them to create the company and develop their medical device innovations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Nico is a direct competitor in minimally invasive brain surgery with its BrainPath system for ICH and tumor evacuation. Both companies target the same neurosurgery use case (minimally invasive access to deep brain lesions) with single-use access and evacuation devices sold to neurosurgery departments.

TypeDirect peer
Description

Penumbra operates in the neurovascular and neurosurgery space with aspiration and access systems used in stroke and ICH procedures. Clearmind competes with Penumbra's Apollo and other systems targeting the same neurosurgeon buyer in hospitals performing hemorrhagic stroke interventions.

TypeBroad incumbent
Description

Integra is a diversified neurosurgery incumbent offering a broad portfolio of instruments, dural repair products, and surgical devices. It overlaps with Clearmind in neurosurgery OR workflows and competes for hospital neurosurgery budgets, although it does not have a directly integrated ICH evacuation platform.

TypeBroad incumbent
Description

Medtronic has a broad neurosurgery and neurovascular portfolio including cranial, spinal, and surgical instrument lines. As a large incumbent, it competes with Clearmind for hospital neurosurgery capital and consumable spend, and could leverage scale to enter integrated ICH evacuation if the market proves attractive.

TypeBroad incumbent
Description

Stryker's neurosurgery and surgical instruments division sells instruments and visualization tools to neurosurgery departments. While it does not directly compete with Clearmind's integrated ICH device, it competes for the same hospital budget and surgeon relationship.

TypeEmerging player
Description

Brainlab provides surgical navigation and planning software that integrates with neurosurgical workflows. Clearmind's Clearpath is designed to integrate with optical and EM navigation systems such as Brainlab's, making Brainlab a complementary/adjacent player rather than a direct device competitor.

TypeBroad incumbent
Description

Karl Storz is a leading endoscopy systems vendor with neuroendoscopy and visualization offerings. As an incumbent endoscopy player, it overlaps with Clearmind on visualization hardware and consumables in neurosurgery, though it has not historically focused on integrated ICH evacuation.

TypeBroad incumbent
Description

Olympus is a global endoscopy leader with surgical endoscopy systems used across specialties including neurosurgery. It is an incumbent in visualization and endoscopic instrumentation but does not currently market a directly integrated ICH evacuation system comparable to Neuroblade.

TypeEmerging player
Description

Viz.ai is an AI-powered stroke imaging and workflow company that routes suspected stroke patients (including ICH) to appropriate hospitals. It is adjacent rather than directly competitive, but it sits in the same hemorrhagic stroke care pathway and influences which surgeons and hospitals Clearmind can target.

TypeEmerging player
Description

RapidAI provides AI-driven imaging and workflow tools for stroke (ischemic and hemorrhagic). Like Viz.ai, it is adjacent to Clearmind in the hemorrhagic stroke care continuum, helping hospitals identify and triage ICH patients who may become candidates for Clearmind's evacuation systems.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clearmind Biomedical

Neurosurgical Medical Devicesclearmindbiomedicalgroup.com

ClearMind Biomedical is a privately held medical device company that develops minimally invasive neurosurgical endoscopy systems for treating intracerebral hemorrhage (hemorrhagic stroke), combining visualization, suction, irrigation, coagulation, and debridement into single-use devices sold to hospital neurosurgery departments in the US and Taiwan.

What Clearmind Biomedical does

ClearMind Biomedical Inc. is a privately held medical device company founded in 2014 with backing from Y Combinator and origins in the Stanford-Taiwan Biomedical Fellowship Program. The company develops and commercializes minimally invasive neurosurgical endoscopy systems for the treatment of intracerebral hemorrhage (ICH), the deadliest form of stroke with reported death rates of 36-60%. Its core technology is a 6.5mm access channel micro-invasive platform that consolidates visualization, illumination, irrigation, suction, coagulation, and powered debridement into single-use neuroendoscope handpieces controlled via reusable high-definition touchscreen monitors.

The product portfolio centers on two generations of the platform. The Axonpen System, FDA 510(k) cleared in the US in 2020 and in Taiwan in 2021, is the first generation multifunctional neuroendoscope with a bendable tip. The Neuroblade System, FDA 510(k) cleared in August 2024, is the second-generation all-in-one device combining bipolar coagulation, morcellator debridement, lens cleaning, suction, and irrigation and is composed of the disposable Neuroblade endoscope, the reusable 15-inch Neuropad touchscreen monitor, and the disposable Clearpath transparent access sheath that integrates with optical and electromagnetic surgical navigation systems. The company has filed 21 patents supporting the Neuroblade platform.

ClearMind operates from dual headquarters in San Jose, California (US) and New Taipei City, Taiwan, employing 11-50 staff across both locations. Its revenue model is enterprise medical device sales of hardware plus disposables, distributed via direct hospital sales targeting neurosurgery departments, with named clinical reference sites at Mt. Sinai Hospital in New York (first US Neuroblade surgery, Dr. Christopher Kellner) and Chang Gang Memorial Hospital in Taiwan (FIM clinical trial site). The company has completed seed, Series A (2017), and Series B (2022, including Darwin Venture Management) funding rounds, leadership comprises CEO Carrey Yang, CTO/CFO Paul Chan, VP & GM Americas J. Dustin Duckett, and BD Manager Penny Huang, and the company pursues a stated objective of enabling a single surgeon to complete ICH procedures in one hour at regional hospitals.

Clearmind Biomedical firmographics

Firmographics
Name
Clearmind Biomedical
Legal name
ClearMind Biomedical Inc.
Website
https://clearmindbiomedicalgroup.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
ClearMind Biomedical is a privately held medical device company that develops minimally invasive neurosurgical endoscopy systems for treating intracerebral hemorrhage (hemorrhagic stroke), combining visualization, suction, irrigation, coagulation, and debridement into single-use devices sold to hospital neurosurgery departments in the US and Taiwan.
Ownership category
akta.pro rank

Clearmind Biomedical industry classification

Industry
Product category
Neurosurgical Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAB
Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHAEAL
Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Neurosurgical endoscopy systems
  • Minimally invasive neurosurgery
  • Intracerebral hemorrhage treatment
  • Neuroendoscopic medical devices
  • Hemorrhagic stroke devices

Where Clearmind Biomedical is headquartered

Location

Headquarters

HQ city
Taipei
HQ country
Taiwan
HQ region
Asia

Offices2 records

Markets served

Clearmind Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Neuroblade System Sales: Sale of the Neuroblade System comprising disposable components (Neuroblade endoscope, Clearpath sheath) and reusable hardware (Neuropad monitor). Medical device capital and consumables model.
  2. Axonpen System Sales: Sale of Axonpen System including disposable endoscope components and reusable monitor (Axon Monitor).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Clearmind Biomedical product offering

Product offering

Core offering

Clearmind Biomedical manufactures and sells micro-invasive neurosurgical endoscopy systems used by neurosurgeons in hospitals to treat intracerebral hemorrhage (ICH) and brain hemorrhage. The product portfolio centers on two FDA 510(k)-cleared platforms - the Axonpen System (multifunctional neuroendoscope with bendable tip and 6.5mm access) and the Neuroblade System (an all-in-one disposable neuroendoscope integrating visualization, illumination, irrigation, suction, coagulation, and powered debridement, used with a reusable touchscreen monitor and disposable access sheath). Devices are sold to hospital neurosurgery departments via direct sales and procurement.

Product overview

Clearmind Biomedical is a medical device company offering a portfolio of minimally invasive neurosurgical systems for the treatment of intracerebral hemorrhage (ICH) and brain hemorrhage. The portfolio consists of two primary product platforms — the Axonpen System and the Neuroblade System — both designed around the company's proprietary micro-invasive technology to enable least-invasive brain surgery. The Axonpen System is a multifunctional endoscope combining visualization, suction, irrigation, and a bendable tip with its companion Axon Monitor, suited for ICH and subdural hematoma procedures. The Neuroblade System is a newer-generation all-in-one platform comprising three components: the Neuroblade single-use neuroendoscope (with integrated coagulation, debridement, suction, and irrigation), the Neuropad reusable touchscreen tablet interface, and the Clearpath disposable transparent access sheath (which also integrates with optical and EM surgical navigation systems). Both platforms target the same clinical indication — ICH evacuation — with a stated objective of enabling a single surgeon to complete procedures in one hour at regional hospitals.

Differentiator

Problem solved

Functional benefit

Brands

  • Axonpen System: Multifunctional neuroendoscope for ICH treatment with disposable endoscope, coagulation system integration, debrider, suction/irrigation, and bendable tip. Features high definition visualization with Axon Monitor.
  • Neuroblade System
  • Clearpath

Products and services

  • Axonpen System A multifunctional neurosurgical endoscope system for the treatment of intracerebral hemorrhage (ICH) and subdural hematomas, combining tissue visualization, suction, irrigation, and a bendable tip into a single minimally invasive operating platform. Requires only a 6.5mm skull channel for brain access, integrates with coagulation systems and homeostasis applicators, and includes the Axon Monitor for high-definition visualization and intraoperative screenshot capture. Targeted at neurosurgery departments in hospitals.
  • Neuroblade System An all-in-one, single-use multifunctional neuroendoscopic system for minimally invasive ICH surgery, integrating bipolar coagulation, morcellator debrider, lens cleaning technology, suction, and irrigation into a single handpiece. The platform comprises three components: Neuroblade (disposable endoscope), Neuropad (reusable 15-inch high-definition touchscreen monitor), and Clearpath (disposable transparent access sheath). FDA 510(k) cleared in 2024 for use by neurosurgeons in hospitals.

Quantifiable outcome

  • 5% mortality rate (vs 35-50% traditional)
  • +4 more outcomes

Companies that use Clearmind Biomedical

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Clearmind Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Clearmind Biomedical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Stanford-Taiwan Biomedical Fellowship ProgramfoundationalStrategic or Co-development PartnerClearMind founders were members of the Stanford-Taiwan Biomedical Fellowship Program, which inspired them to create the company and develop their medical device innovations.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Clearmind Biomedical competitors and assessment

Company assessment

Direct peers

  • Nico Corporation: Nico is a direct competitor in minimally invasive brain surgery with its BrainPath system for ICH and tumor evacuation. Both companies target the same neurosurgery use case (minimally invasive access to deep brain lesions) with single-use access and evacuation devices sold to neurosurgery departments.
  • Penumbra: Penumbra operates in the neurovascular and neurosurgery space with aspiration and access systems used in stroke and ICH procedures. Clearmind competes with Penumbra's Apollo and other systems targeting the same neurosurgeon buyer in hospitals performing hemorrhagic stroke interventions.

Broad incumbents

  • Integra LifeSciences: Integra is a diversified neurosurgery incumbent offering a broad portfolio of instruments, dural repair products, and surgical devices. It overlaps with Clearmind in neurosurgery OR workflows and competes for hospital neurosurgery budgets, although it does not have a directly integrated ICH evacuation platform.
  • Medtronic: Medtronic has a broad neurosurgery and neurovascular portfolio including cranial, spinal, and surgical instrument lines. As a large incumbent, it competes with Clearmind for hospital neurosurgery capital and consumable spend, and could leverage scale to enter integrated ICH evacuation if the market proves attractive.
  • Stryker: Stryker's neurosurgery and surgical instruments division sells instruments and visualization tools to neurosurgery departments. While it does not directly compete with Clearmind's integrated ICH device, it competes for the same hospital budget and surgeon relationship.
  • Karl Storz: Karl Storz is a leading endoscopy systems vendor with neuroendoscopy and visualization offerings. As an incumbent endoscopy player, it overlaps with Clearmind on visualization hardware and consumables in neurosurgery, though it has not historically focused on integrated ICH evacuation.
  • Olympus: Olympus is a global endoscopy leader with surgical endoscopy systems used across specialties including neurosurgery. It is an incumbent in visualization and endoscopic instrumentation but does not currently market a directly integrated ICH evacuation system comparable to Neuroblade.

Emerging players

  • Brainlab: Brainlab provides surgical navigation and planning software that integrates with neurosurgical workflows. Clearmind's Clearpath is designed to integrate with optical and EM navigation systems such as Brainlab's, making Brainlab a complementary/adjacent player rather than a direct device competitor.
  • Viz.ai: Viz.ai is an AI-powered stroke imaging and workflow company that routes suspected stroke patients (including ICH) to appropriate hospitals. It is adjacent rather than directly competitive, but it sits in the same hemorrhagic stroke care pathway and influences which surgeons and hospitals Clearmind can target.
  • RapidAI: RapidAI provides AI-driven imaging and workflow tools for stroke (ischemic and hemorrhagic). Like Viz.ai, it is adjacent to Clearmind in the hemorrhagic stroke care continuum, helping hospitals identify and triage ICH patients who may become candidates for Clearmind's evacuation systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Clearmind Biomedical social profiles

Digital presence

Clearmind Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clearmind Biomedical leadership team

Management profile

Number of profiles

Profiles6 records

Clearmind Biomedical funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clearmind Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clearmind Biomedical

What does Clearmind Biomedical do?

Clearmind Biomedical manufactures and sells micro-invasive neurosurgical endoscopy systems used by neurosurgeons in hospitals to treat intracerebral hemorrhage (ICH) and brain hemorrhage. The product portfolio centers on two FDA 510(k)-cleared platforms - the Axonpen System (multifunctional neuroendoscope with bendable tip and 6.5mm access) and the Neuroblade System (an all-in-one disposable neuroendoscope integrating visualization, illumination, irrigation, suction, coagulation, and powered debridement, used with a reusable touchscreen monitor and disposable access sheath). Devices are sold to hospital neurosurgery departments via direct sales and procurement.

Is Clearmind Biomedical a public or private company?

Clearmind Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Clearmind Biomedical founded?

Clearmind Biomedical was founded in 2014. It employs 1 to 10 people.

Where is Clearmind Biomedical based?

Clearmind Biomedical is headquartered in Taipei, Taiwan, in the Asia region.

How does Clearmind Biomedical make money?

Two revenue lines are on record. Neuroblade System Sales are the primary driver. The others are axonpen System Sales.

Who are Clearmind Biomedical's main competitors?

Direct peers on record are Nico Corporation and Penumbra. Broad incumbents are Integra LifeSciences, Medtronic, Stryker, Karl Storz and Olympus. Emerging players are Brainlab, Viz.ai and RapidAI.

Does Clearmind Biomedical have an API?

No public API is recorded for Clearmind Biomedical.

What industry is Clearmind Biomedical in?

Clearmind Biomedical's product category is Neurosurgical Medical Devices. Its primary akta.pro industry code is HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation), with a secondary code of HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals